A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Study of INCB106385 Alone or in Combination with INCMGA00012 in Patients with Advanced Cancer
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAT6263
U.S. Govt. ID: NCT04580485
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: INCB106385 and INCMGA00012 are drugs being studied by Incyte Corporation for use in the treatment of advanced cancer. These study drugs are known as immune therapies, which are designed to help your immune system become more active and possibly fight your cancer. INCB106385 will be tested either alone (monotherapy) or in combination with INCMGA00012. The purpose of this trial is to test the safety and tolerability of the monotherapy or combination therapy, find out what effects the study drugs have on people and their cancer, and to select the safe and tolerable dose of INCB106385 as monotherapy and in combination with INCMGA00012. Cancers may include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, ovarian cancer, head and neck/oral cancers, lung cancer, pancreatic cancer, and prostate cancer.
Investigator
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced cancer? Yes No
Have you had progression of your cancer with prior standard therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162